THE ROLE OF SURGICAL TREATMENT OF SUPERFICIAL BLADDER TUMOUR
Authors:
G. Varga
Authors‘ workplace:
Urologická klinika FN Brno, LF MU Brno
Published in:
Urol List 2011; 9(3): 16-21
Overview
According to the National oncologic registry data bladder cancer represented the 6th most common malignancy in men and 13th most common malignancy in women in 2005. Although the swings in the bladder carcinoma incidence during time period does not correspond to the trends observed in renal and prostate cancer, an average increase of 6% was reported between 1990 and 2005. There has been a slow increase in the mortality curve in Czech Republic (in comparison with the increase in incidence during last two decades) demonstrating an improvement in diagnostics with cancer detection in its early stage. The most common histological type of bladder malignancy is urothelial cancer (also transitional cell carcinoma) representing 93 % of all malignant bladder neoplasias. The remaining 7% comprises other types of malignant diseases. Approximately in 75–85% of patients tumor invading into mucosa is present. In this case we are talking about non-invasive, i.e. superficial carcinoma. The role of surgical therapy in this stage has a crucial role since it is the predicator of prognosis [1,2].
Key words:
non-muscle invasive bladder, carcinomatransurethral resection of bladder, radical cystectomy
Sources
1. http://www.svod.cz/analysez
2. Babjuk M. Transurethral Resection of Non–muscle-invasive Bladder Cancer. Eur Urol 2009; Suppl 8: 542–548.
3. Babjuk M, Oosterlinck W, Sylvester R et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54(2): 303–314.
4. Babjuk M, Oosterlinck W, Sylvester R et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/professional-resources/ guidelines/online.
5. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumours of the bladder: international consensus panel. Urology 2005; 66(Suppl 1): 108–125.
6. Herr HW. High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumour. Semin Urol Oncol 1997; 15(3): 142–146.
7. Babjuk M. Terapie povrchových nádorů močového měchýře. In: Dvořaček J, Babjuk M. Onkourologie. Praha: Galén 2005. 139–147.
8. Grimm MO, Steinhoff C, Simon X et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003; 170 (2 Pt 1): 433–437.
9. Brausi M, Collette L, Kurth K et al. EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate atfirst follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41(5): 523–531.
10. Friedrich M et al. Reduction of early tumour recurrences in superficial bladder carcinoma using an extended resection protocol. Eur Urol 2002; Suppl 1(1): 3–206, abstract 470.
11. Herr HW, Donat MS. Quality control in transurethral resection of bladder tumors. BJU Int 2008; 102 (9 pt B): 1242–1246.
12. van der Meijden A, Oosterlinck W, Brausi M et al. Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1999; 35(4): 267–271.
13. Nieder AM, Meinbach DS, Kim SS et al. Transurethral bladder tumor resection: intraoperative and postoperative complications in a residency setting. J Urol 2005; 174(6): 2307–2309.
14. Thomas K, O’Brien T. Improving transurethral resection of bladder tumour: the gold standard for diagnosis and reatment of bladder tumours. Eur Urol 2008; 7 (Suppl): 524–528.
15. Brausi MA, Gavioli M, Peracchia G et al. Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumors (NMIBT): experience of a single institution. Eur Urol 2008; 7 (Suppl): 180.
16. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the Bladder: International Consensus Panel. Urology 2006; 66 (6 Suppl 1): 108–125.
17. Witjes JA, Melissen DOTM, Kiemeney LALM. Current praktice in the management of superficial bladder cancer in the Netherlands and Belgian Flanders: a survey. Eur Urol 2006; 49(3): 478–484.
18. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001; 19(3): 666–675.
19. Jakse G, Algaba F, Malmstrom PU et al. A second- look TUR in T1 transitional cell carcinoma: why? Eur Urol 2004; 45(5): 539–546.
20. Huguet J, Crego M, Sabate S et al. Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48(1): 53–59.
21. Herr HW. Extravesical tumour relapse in patients with superficial bladder tumours. J ClinOncol 1998; 16(3): 1099–1102.
22. Vallancien G, Abou El Fettouh H, Cathelineau X et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002; 168(6): 2413.
23. Hautmann RE, Stein JP. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin NorthAm 2005; 32(2): 177–185.
24. Lamm DL, Crawford ED, Blumenstein B et al. Maintenance BCG immunotherapy for recurrent Ta, T1 and Tis transitional cell carcinoma of the bladder: a randomized prospective Southwest Oncology Group study. J Urol 2000; 163(4): 1124–1129.
25. Oesterlinck W, Lobel B, Jakse G et al. Guidelines on bladder cancer. Eur Urol 2002; 41(2): 105–112.
26. Vít V. Neinvazivní karcinom močového měchýře- kdy je indikována adjuvantní intravezikální instilační léčba a co dělat při jejím selhání? Urol List 2008; 6(2): 16–24.
27. Cookson MS, Herr HW, Zhang ZF et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997; 158(1): 62.
28. Cheng L, Weaver AL, Leibovich BC et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000; 88(10): 2326.
29. Gattegno B. T1G3 Bladder Cancer: Conservative Management or Cystectomy? Eur Urol 2004; 45(4): 399–400.
30. Hendricksen K, Witjes JA.Treatment of Intermediate-Risk Non–Muscle-Invasive Bladder Cancer (NMIBC). Eur Urol 2007; Suppl 6: 800–808.
31. Raj GV, Herr H, Serio AM et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007; 177(4): 1283–1286.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2011 Issue 3
Most read in this issue
- ILEAL NEOBLADDER AND ITS VARIANTS
- Treatment of muscle-invasive and metastatic bladder cancer – update of the EAU Guidelines
- INTRAVESICAL INSTILLATION THERAPY IN THE TREATMENT OF SUPERFICIAL BLADDER CARCINOMA
- METHODS OF NON-INVASIVE DIAGNOSTICS AND MONITORING OF URINARY BLADDER CANCER